During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

SAN ANTONIO, October 18, 2024--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...

JACKSON, Miss. (WJTV) – Registration is open for the University of Mississippi Medical Center (UMMC) Cancer Center and ...

Research from the Berger lab at Fred Hutch identifies the deubiquitinase USP9X as an important factor helping to increase ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Cervical cancer remains the most widespread cause of cancer death in women in the country, accounting for 12 percent of all cancer deaths recorded in Zimbabwe. Prostate cancer is the second most ...

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...